Is CELC or ALMS more profitable?

Celcuity has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Alumis -5,933.46% -93.15% -74.50%

Does the media refer more to CELC or ALMS?

In the previous week, Alumis had 4 more articles in the media than Celcuity. MarketBeat recorded 8 mentions for Alumis and 4 mentions for Celcuity. Celcuity's average media sentiment score of 0.61 beat Alumis' score of 0.42 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, TLX or ALMS?

Telix Pharmaceuticals has higher revenue and earnings than Alumis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.74 -$7.12M N/A N/A Alumis $24.05M 38.53 -$243.32M -$3.86 N/A

Does the media refer more to TLX or ALMS?

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Telix Pharmaceuticals and 8 mentions for Alumis. Alumis' average media sentiment score of 0.42 beat Telix Pharmaceuticals' score of 0.08 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, VCYT or ALMS?

Veracyte has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $561.90M 6.47 $66.35M $1.41 32.08 Alumis $24.05M 38.53 -$243.32M -$3.86 N/A

Is VCYT or ALMS more profitable?

Veracyte has a net margin of 20.37% compared to Alumis' net margin of -5,933.46%. Veracyte's return on equity of 9.26% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 20.37% 9.26% 8.61% Alumis -5,933.46% -93.15% -74.50%

Does the media prefer VCYT or ALMS?

In the previous week, Veracyte and Veracyte both had 8 articles in the media. Veracyte's average media sentiment score of 0.54 beat Alumis' score of 0.42 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ACAD or ALMS?

In the previous week, ACADIA Pharmaceuticals had 6 more articles in the media than Alumis. MarketBeat recorded 14 mentions for ACADIA Pharmaceuticals and 8 mentions for Alumis. Alumis' average media sentiment score of 0.42 beat ACADIA Pharmaceuticals' score of 0.07 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Alumis 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, CDNA or ALMS?

CareDx has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CareDx $458.09M 7.19 -$21.35M $2.07 30.76 Alumis $24.05M 38.53 -$243.32M -$3.86 N/A

Is CDNA or ALMS more profitable?

CareDx has a net margin of 24.23% compared to Alumis' net margin of -5,933.46%. CareDx's return on equity of 2.87% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets CareDx 24.23% 2.87% 2.17% Alumis -5,933.46% -93.15% -74.50%

Does the media prefer CDNA or ALMS?

In the previous week, Alumis had 2 more articles in the media than CareDx. MarketBeat recorded 8 mentions for Alumis and 6 mentions for CareDx. CareDx's average media sentiment score of 0.68 beat Alumis' score of 0.42 indicating that CareDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alumis (ALMS) Competitors

$7.16 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.12 -0.04 (-0.50%)

As of 04:24 AM Eastern

Compare

ALMS vs. CELC, TLX, VCYT, ACAD, and CDNA

Should you buy Alumis stock or one of its competitors? Alumis's main competitors and comparable companies include Celcuity (CELC), Telix Pharmaceuticals (TLX), Veracyte (VCYT), ACADIA Pharmaceuticals (ACAD), and CareDx (CDNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alumis compare to Celcuity?

Celcuity (NASDAQ:CELC) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Celcuity currently has a consensus target price of $154.25, indicating a potential upside of 127.04%. Alumis has a consensus target price of $33.27, indicating a potential upside of 364.70%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Alumis had 4 more articles in the media than Celcuity. MarketBeat recorded 8 mentions for Alumis and 4 mentions for Celcuity. Celcuity's average media sentiment score of 0.61 beat Alumis' score of 0.42 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celcuity has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Alumis has a beta of -0.38, suggesting that its share price is 138% less volatile than the broader market.

Celcuity has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Alumis	-5,933.46%	-93.15%	-74.50%

63.3% of Celcuity shares are owned by institutional investors. 13.3% of Celcuity shares are owned by company insiders. Comparatively, 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Celcuity has higher earnings, but lower revenue than Alumis. Celcuity is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Alumis	$24.05M	38.53	-$243.32M	-$3.86	N/A

Summary

Alumis beats Celcuity on 9 of the 15 factors compared between the two stocks.

How does Alumis compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Telix Pharmaceuticals has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Telix Pharmaceuticals' return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Alumis	-5,933.46%	-93.15%	-74.50%

Telix Pharmaceuticals has higher revenue and earnings than Alumis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.74	-$7.12M	N/A	N/A
Alumis	$24.05M	38.53	-$243.32M	-$3.86	N/A

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Telix Pharmaceuticals and 8 mentions for Alumis. Alumis' average media sentiment score of 0.42 beat Telix Pharmaceuticals' score of 0.08 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market. Comparatively, Alumis has a beta of -0.38, indicating that its stock price is 138% less volatile than the broader market.

Telix Pharmaceuticals currently has a consensus price target of $20.50, indicating a potential upside of 82.87%. Alumis has a consensus price target of $33.27, indicating a potential upside of 364.70%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Telix Pharmaceuticals beats Alumis on 7 of the 13 factors compared between the two stocks.

How does Alumis compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Veracyte has a net margin of 20.37% compared to Alumis' net margin of -5,933.46%. Veracyte's return on equity of 9.26% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Alumis	-5,933.46%	-93.15%	-74.50%

Veracyte presently has a consensus price target of $55.78, suggesting a potential upside of 23.32%. Alumis has a consensus price target of $33.27, suggesting a potential upside of 364.70%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Veracyte has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, Alumis has a beta of -0.38, meaning that its stock price is 138% less volatile than the broader market.

In the previous week, Veracyte and Veracyte both had 8 articles in the media. Veracyte's average media sentiment score of 0.54 beat Alumis' score of 0.42 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veracyte has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$561.90M	6.47	$66.35M	$1.41	32.08
Alumis	$24.05M	38.53	-$243.32M	-$3.86	N/A

Summary

Veracyte beats Alumis on 9 of the 13 factors compared between the two stocks.

How does Alumis compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

ACADIA Pharmaceuticals presently has a consensus target price of $32.71, suggesting a potential upside of 65.37%. Alumis has a consensus target price of $33.27, suggesting a potential upside of 364.70%. Given Alumis' stronger consensus rating and higher possible upside, analysts plainly believe Alumis is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

ACADIA Pharmaceuticals has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Alumis has a beta of -0.38, suggesting that its share price is 138% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Alumis' net margin of -5,933.46%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Alumis	-5,933.46%	-93.15%	-74.50%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 33.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, ACADIA Pharmaceuticals had 6 more articles in the media than Alumis. MarketBeat recorded 14 mentions for ACADIA Pharmaceuticals and 8 mentions for Alumis. Alumis' average media sentiment score of 0.42 beat ACADIA Pharmaceuticals' score of 0.07 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alumis	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.14B	2.99	$391M	$2.22	8.91
Alumis	$24.05M	38.53	-$243.32M	-$3.86	N/A

Summary

ACADIA Pharmaceuticals beats Alumis on 11 of the 17 factors compared between the two stocks.

How does Alumis compare to CareDx?

CareDx (NASDAQ:CDNA) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

CareDx currently has a consensus target price of $54.00, suggesting a potential downside of 15.19%. Alumis has a consensus target price of $33.27, suggesting a potential upside of 364.70%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

CareDx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Comparatively, Alumis has a beta of -0.38, suggesting that its stock price is 138% less volatile than the broader market.

In the previous week, Alumis had 2 more articles in the media than CareDx. MarketBeat recorded 8 mentions for Alumis and 6 mentions for CareDx. CareDx's average media sentiment score of 0.68 beat Alumis' score of 0.42 indicating that CareDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CareDx has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$458.09M	7.19	-$21.35M	$2.07	30.76
Alumis	$24.05M	38.53	-$243.32M	-$3.86	N/A

CareDx has a net margin of 24.23% compared to Alumis' net margin of -5,933.46%. CareDx's return on equity of 2.87% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Alumis	-5,933.46%	-93.15%	-74.50%

Summary

CareDx beats Alumis on 9 of the 15 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMS vs. The Competition

Export

Metric	Alumis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$926.72M	$3.93B	$7.25B	$13.28B
Dividend Yield	N/A	3.65%	2.52%	22.58%
P/E Ratio	-1.85	13.62	275.59	26.13
Price / Sales	38.53	1,239.52	595.29	89.84
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	2.49	16.60	10.58	6.16
Net Income	-$243.32M	-$22.69M	$3.50B	$381.12M
7 Day Performance	4.68%	-1.66%	-1.21%	-1.43%
1 Month Performance	-22.00%	-8.00%	-4.02%	-3.36%
1 Year Performance	61.26%	14.32%	7.17%	1.49%

Alumis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMS Alumis	3.7394 of 5 stars	$7.16 flat	$33.27 +364.7%	+61.3%	$926.72M	$24.05M	N/A	239	News Coverage Positive News Short Interest Increase
CELC Celcuity	2.7319 of 5 stars	$72.10 -4.0%	$154.25 +113.9%	+47.5%	$3.68B	N/A	N/A	155
TLX Telix Pharmaceuticals	4.4812 of 5 stars	$10.55 -1.6%	$20.50 +94.3%	+17.1%	$3.64B	$803.79M	N/A	1,184
VCYT Veracyte	4.1582 of 5 stars	$45.81 +3.7%	$55.78 +21.8%	+30.0%	$3.55B	$517.15M	32.49	755	Analyst Downgrade
ACAD ACADIA Pharmaceuticals	4.7304 of 5 stars	$19.95 +0.3%	$32.76 +64.2%	-1.4%	$3.43B	$1.14B	8.99	798	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMS) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alumis (ALMS) Competitors